Women with cervical intraepithelial neoplasia grade 3 (CIN3) have a long‐lasting increased risk for noncervical high‐risk human papillomavirus (hrHPV)‐related (pre)malignancies. The aim of our study was to estimate this risk in women with recurrent CIN3 compared to women without a history of CIN3 and women with a single episode of CIN3. Women with a CIN3 diagnosis between 1990 and 2010 were obtained from the Dutch Pathology Registry (PALGA) and matched with a control group of women without CIN3. Analysis has been conducted in a subset of women with recurrent CIN3, defined as reoccurrence minimally 2 years post‐treatment. Cases of noncervical hrHPV‐related (pre)malignancies of the anus, vulva, vagina and oropharynx were identified until 2015 and incidence rate ratios (IRRs) were estimated. Then, 1,797 women with recurrent CIN3 were included with a median age of 34 years (range 18–76) and 31,594 person‐years of follow‐up. Women with recurrent CIN3 had an increased risk of developing noncervical hrHPV‐related (pre)malignancies compared to women without CIN3 with an IRR of 25.96 (95%CI 6.32–106.58). The IRR was 2.48 (95% CI 1.87–3.30) compared to women with a single episode of CIN3. Studies on posttreatment follow‐up and prophylactic hrHPV vaccination are warranted.

中文翻译：

---

复发性子宫颈上皮内瘤变3级后非宫颈高危型人乳头瘤病毒相关（前）恶性肿瘤的相对风险：一项基于人群的研究。

患有宫颈上皮内瘤变3级（CIN3）的妇女长期存在与非宫颈高危型人乳头瘤病毒（hrHPV）相关的（恶性）恶性肿瘤的风险。我们研究的目的是评估与没有CIN3病史和单发CIN3的女性相比，复发CIN3的女性的这种风险。1990年至2010年间诊断为CIN3的女性来自荷兰病理注册中心（PALGA），并与没有CIN3的对照组女性配对。已对一部分CIN3复发的女性进行了分析，定义为治疗后至少2年复发。直到2015年为止，肛门，外阴，阴道和口咽的非宫颈hrHPV相关（恶性）恶性肿瘤病例均已确定，并估算了发病率比率（IRR）。然后，1 纳入797例CIN3复发女性，中位年龄34岁（范围18-76），随访31594人年。与没有CIN3的女性相比，具有CIN3复发的女性患非宫颈hrHPV相关（恶性）的风险更高，其IRR为25.96（95％CI 6.32–106.58）。与单发CIN3的女性相比，IRR为2.48（95％CI 1.87–3.30）。必须对治疗后的随访和预防性hrHPV疫苗进行研究。